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Gene variability related to carcinogen activation and 
detoxification may interfere with susceptibility to head and 
neck cancer. Aim: To investigate the relation between GSTT1 
and GSTM1 null polymorphisms and the risk of head and 
neck squamous cell carcinoma in cigarette smokers. Material 
and Method: A case-control study conducted at the Sao 
Jose do Rio Preto Medical School, Brazil. GSTM1 and GSTT1 
null genotype frequencies were evaluated by multiplex PCR 
in 45 cigarette smokers with head and neck squamous cell 
carcinomas and 45 cigarette smokers without this disease. 
Results: The oral cavity was the most prevalent tumor site 
for squamous cell carcinoma. The GSTT1 null genotype was 
found in 33.3% of the Experimental Group and 23.3% of the 
Control Group (p= 0.311). Experimental and Control Groups 
had GSTM1 null genotype frequencies of 35% and 48.3% 
(p=0.582). No association between alcohol consumption 
and GSTT1 and GSTMI null genotypes was found in these 
groups (p-values>0.05). There were more men, and alcohol 
consumption was prevalent in both groups. Conclusion: In 
this study we were unable to show a correlation between 
GSTM1 and GSTT1 genotypes and the development of head 
and neck squamous cell carcinomas in cigarette smokers. 
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INTRODUCTION
Head and neck neoplasms are responsible for 
many deaths worldwide, being the sixth cause of death 
by câncer.1 The most frequent histological type is the 
squamous cell carcinoma, which is found in over 90% of 
cases,2-4 and is usually associated with the use of alcohol 
and tobacco.5-9 It is known that cigarette smoke is a com-
plex mixture of over 4,000 substances, of which at least 
40 are carcinogenic, initiating or promoting tumors in 
animals.10 Levels of electrophilic products launched into 
the bloodstream depend on the action of enzymes invol-
ved in biometabolism, which includes activation (Phase I) 
and detoxification (Phase II) of chemical compounds.10,11 
Polymorphisms in genes that codify these enzymes may 
alter their expression or function, altering carcinogenic 
compounds biometabolism12.
Various polymorphic genes that code enzymes 
involved in carcinogen biotransformation have been as-
sociated with cancer development.13-22 Two genes in par-
ticular - GSTT1 and GSTM1 - that code phase II enzymes 
belonging to the glutathione S-transferases (GSTs) family 
seem relevant for susceptibility to head and neck squamous 
cell carcinoma; they detoxify carcinogenic tobacco smoke 
reactive metabolites.11-12,13,15,18,20,23
The GSTM1 gene is polymorphic in humans, in-
cluding a null-activity allele (GSTM1-) due to a major 
genic deletion, and two functional alleles (GSTM1A and 
GSTM1B). The GSTT1 gene is also polymorphic in humans, 
and may have a deletion null genotype.24,25 Individuals that 
have one of these null genotypes in homozygosis may be 
grouped into the negative conjugating phenotype, where 
there is complete loss of enzyme activity,26,27 while those 
that have at least one functional allele are grouped in the 
positive conjugating phenotype.28
Thus, individual gene variability in the metabolic 
activation and detoxification process appears to be crucial 
to head and neck cancer susceptibility.
This study aimed to identify GSTT1 and GSTM1 gene 
null genotypes in smokers with head and neck squamous 
cell carcinoma and to compare these frequencies with 
those seen in smokers without a history of cancer, to 
identify possible susceptibility biomarkers for head and 
neck cancer.
 MATERIAL AND METHODS
Individuals diagnosed with squamous cell head and 
neck carcinomas confirmed by histopathology came from 
the Department of Otorhinolaryngology and Head and 
Neck Surgery of the Navy Hospital / Medical School of 
São José do Rio Preto and the Arnaldo Vieira de Carvalho 
Institute, SP. The control group included individuals with 
no history of neoplastic disease, paired by gender, age, 
ethnic group and use of alcoholic beverages. All subjects 
(patients and controls) were smokers. Individuals were 
included in the study after signing a free and informed 
consent form, and all information was obtained using a 
confidential standardized data-collection questionnaire 
(gender, ethnic group, smoking and use of alcohol). In-
formation on smoking and alcohol-drinking was limited to 
a definition of user or non-user. The study was approved 
by the Research Ethics Committee of the Sao Jose do Rio 
Preto Medical School (CEP-FAMERP - 5639/2002) and the 
National Research Ethics Council (CONEP - legal process 
nº 842/2003).
Genomic DNA was extracted from peripheral blood 
according to the Abdel-Rahman et al technique.29 A sample 
of peripheral blood was collected in a test tube containing 
anticoagulant (EDTA) and lymphocytes were isolated 
using the Ficoll-Paque Plus. Genomic DNA was obtained 
by adding SDS (Sodium Dodecyl Sulphate), proteinase K 
and RNAse A to the isolated lymphocytes. Following NaCl 
purification, DNA was precipitated with ethanol and stored 
at -20ºC in a Tris-EDTA buffer solution for later analysis.
The analysis of GSTT1 and GSTM1 genes was simul-
taneously done by the chain reaction (PCR) according to 
Abdel-Rahman et al.30 Amplification of the DNA sequence 
of interest was obtained in 35 cycles that included DNA 
denaturing steps at 94ºC for 2 minutes, annealing of re-
action-initiator sequences (primers) at 59ºC for 1 minute, 
and DNA chain extension by nucleotide addition at 72ºC 
for 1 minute. A CYP1A1 gene exon 7 sequence was    co-
amplified to serve as an internal amplification control. PCR 
products were analyzed in agarose gel at 1.5%, stained 
with ethydium bromide, and the null genotype (both alle-
les with a deletion) for the GSTT1 and GSTM1 genes was 
identified by the absence of amplification fragments of 480 
base pairs (bp) and 219 bp respectively. Presence of the 
312 bp fragment corresponded to the amplified CYP1A1 
gene sequence, which was evidence of a successful am-
plification reaction.
Demographics were presented as mean ± standard 
deviation (SD) or proportions. For the statistical analysis 
of the genotype frequencies obtained we used the exact 
Fisher test, with a significance level below 5%.
 RESULTS
Demography data: 120 individuals were recruited, 
of which 60 had head and neck squamous cell carcino-
ma (average age 54.6 ± 8 years) and 60 had no history 
of neoplastic disease (average age 54 ± 9 years). Men 
predominated (90% men vs. 10% women) and there were 
more alcohol drinkers (70% alcoholics vs. 30% non-alco-
holics). 
Primary sites: all head and neck squamous cell car-
cinoma cases were diagnosed and confirmed by pathology 
exams. The distribution of the primary tumor site is shown 
on Table 1. Mouth cancers were the most frequent type. 
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Frequency of polymorphisms: The GSTT1 null ge-
notype [-] was found in 33.3% (20 of 60) of patients and 
Table 1. Distribution of head and neck cancer cases by tumor site.
Site Number (%)
Oral cavity 26 (43,3)
Supraglottic 15 (25)
Glottic 6 (10)
Subglottic 1 (1,7)
Pharynx 4 (6,7)
Hypopharynx 5 (8,3)
Other unknown primary sites 3 (5)
in 23.3% (14 of 60) of controls (P = 0.311). The GSTM1 
null genotype [-] was found in 21 (35%) of patients and 
29 (48.3 %) of controls (p = 0.582). The combined GSTT1 
and GSTM1 gene null genotype was seen in 10% (6 of 
60) of patients and in 8.3% (5 of 60) of controls (p = 1.0). 
The most frequent genotypic combination, considering 
the presence of an unfavorable genotype (null GST), was 
GSTT1 [+] / GSTM1 [-] in 31.6% (19 of 60) of patients and 
40% (24 of 60) of controls (p = 0.353) (Table 2).
Genotypes were grouped by tumor site (Table 3) 
and there was no correlation with GSTT1 and GSTM1 null 
genotypes.
Statistical analysis did not reveal any relation be-
Table 2. GSTT1 and GSTM1 genotype distribution in the experimental 
and control groups. 
Genotypes*
Patients (n = 60)
n (%)
Control (n=60)
n (%)
Individual
GSTT1 [-] 20 (33,3) 14 (23,3)
GSTM1[-] 25 (41,7) 29 (48,3)
Combined GSTT1/GSTM1
[-] / [-] 06 (10,0) 05 (8,3)
[+] / [+] 21 (35,0) 22 (36,7)
[+] / [-] 19 (31,6) 24 (40,0)
[-] / [+] 14 (23,3) 09 (15,0)
* Null genotypes [-], non-null [+].
Table 3. GSTT1 and GSTM1 genotype distribution by tumor site.
Genotypes Oral Cavity Supraglottic Glottic Subglottic Pharynx Hypopharynx Others
GSTT1 [+] 20 11 2 0 3 3 2
GSTT1 [-] 6 4 4 1 1 2 1
GSTM1 [+] 13 10 4 1 2 2 2
GSTM1 [-] 13 5 2 0 2 3 1
* Null genotypes [-], non-null [+].
tween alcohol use and GSTT1 and GSTM1 null genotypes 
[-] when we compared alcohol-drinking patients and 
controls (GSTT1, p = 0.34; GSTM1, p = 0.28; GSTM1[-] / 
GSTT1[-], p = 1.0).
 DISCUSSION
Epidemiological data has suggested that alcohol 
use and smoking are the main risk factors for malignant 
transformation in head and neck cancers.31,32 It is difficult 
to assess the individual effect of these agents on the ge-
nesis of head and neck cancer. Smokers tend to consume 
alcohol and alcohol drinkers tend to smoke. Furthermore, 
in past decades the evidence has show that both factors 
operate synergistically, and as such may be the main cause 
of tumors.32
Studies have shown an association between alcohol 
drinking and the development of head and neck tumors 
when taking into account exposure time and the amount 
of alcohol consumed.12,34 In our study, 70% of patients with 
cancer drink alcoholic beverages, which strengthens the 
association between alcohol use and the development of 
head and neck cancer. This is especially true in a sample 
that includes smokers. Unfortunately we were unable to 
obtain information about the amount of alcohol that was 
consumed or the exposure time.
The higher number of men in this study corrobo-
rates findings by Drummond et al,22 although our case 
number is not sufficient to explain this gender difference. 
An epidemiological study done at the A. C. Camargo 
Hospital in the state of Sao Paulo, Brazil, showed that 
the predominance of men in patients with mouth cancer 
appears to reflect differences in alcohol use and smoking 
between men and women in this country.35
The most frequent tumor site in our patients was 
the mouth, which is also the most frequent site for head 
and neck tumors reported in literature.36 This anatomical 
distribution may be explained by the fact that our sample 
was made up of smokers, most of which also consumed 
alcoholic beverages, reflecting the fact that the upper 
aerodigestive tract is more directly exposed to tobacco 
and alcohol.
GSTT1 and GSTM1 polymorphism studies done in 
Brazilian sub-populations reveal similar frequencies for 
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both genotypes. Rossit et al,37 in a study among popu-
lations from the states of Para and Sao Paulo, showed 
frequencies of 18 and 47.3% for GSTT1 and GSTM1 gene 
null genotypes, respectively. Rossini et al,38 revealed 
frequencies of 25.4% for GSTT1 [-] and 42.1% for GSTM1 
[-] in the state of Rio de Janeiro. Our study showed simi-
lar frequencies for these genotypes (24.4 and 17.8% for 
GSTT1 [-] in patients and controls, and 44.4 and 48.9% for 
GSTM1 [-] in patients and controls). Higher GSTT1 [-] and 
GSTM1 [-] polymorphism frequencies were observed by 
Drummond et al.21,22 in Brazilian smokers with oral cavity 
squamous cell carcinoma (81.8% for GSTT1 [-] and 70.5% 
for GSTM1 [-]).
GSTT1 and GSTM1 polymorphism studies done in 
head and neck carcinomas are contradictory. Various au-
thors have demonstrated an association with the GSTM1 
null genotype [-],14,15,20,21,38,40,41 which other authors have 
not seen.5,16,42,43 A relation with the GSTT1 null genotype 
[-] was also shown in some studies,15,20,22,44 which was not 
seen in other studies.5,16,37,39,41,43,46 The combination of these 
higher risk and null genotypes has also been observed 
in this type of carcinoma.14,41 Moreover, both exposure 
time and intensity to carcinogenic (alcohol and tobacco) 
may influence on the interaction of these genotypes for 
the development of this kind of neoplasia12,34, and these 
data were not considered in our study. A study by Konig-
Greger et al47 showed that GSTM1-enzyme activity was 
significantly reduced in patients with head and neck car-
cinoma compared to controls, although it did not depend 
on the unfavorable GSTM1 genotype, which may suggest 
that other enzymes participate as regulators.
Interestingly, Evans et al13 found that the positive 
GSTT1 genotype [+] is associated with an increased risk of 
head and neck squamous cell carcinoma in smokers (OR 
= 1.6; CI 95% = 1.1-2.5) and that the GSTT1 null genotype 
[-] may protect individuals against the development of this 
cancer. Although usually GSTs are considered detoxifica-
tion enzymes, for certain specific chemical substrates such 
as dichloromethane (DCM), conjugation of glutathione 
with the GSTT1 enzyme may activate an electrophilic 
component, resulting in mutagenic potential.48,49 Although 
DCM is not associated with tobacco, tobacco byproducts 
may gain carcinogenicity by GSTT1-enzyme mediated ac-
tivation. Two other papers have also shown an increased 
risk of coronary disease and peripheral vascular disease 
in smokers with a GSTT1 genotype [+].50,51 
 CONCLUSION
This study did not allow us to establish any corre-
lation between GSTT1 and GSTM1 null genotypes and the 
development of head and neck squamous cell carcinoma 
in smokers.
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